Table 2.

Tabular representation of included studies.

Author	Country	Population	Primary Outcome	Intervention Type (No. of Patients)	Dose of Vit K	Follow-Up Period	Age (yrs)
[16]	Japan	Patients with rheumatoid arthritis	BMD	Group (Vit K)- 21	45 mg	24 M	61.4 ± 9.6 62.3 ± 9.0 63.4 ± 7.2
				Group (K+ Risedronate)—29
				Group (K+ Etidronate)—29
				Total—79
[13]	Japan	Postmenopausal female	BMD	Group (Alendronate + K2)—26	45 mg	12 M	69.8 (8.7) 67.0 (6.6)
				Group(Vit K2)—22
				Total—48
[25]	New York	Postmenopausal female	BMD & OC	Group (Placebo)—60	1 mg	3 Y	55.1 (2.9) 55.3 (2.8)
				Group (Mineral+ Vit D)—46
				Group (Mineral+ Vit D + K1)—56
				Total—162
[14]	New York	Postmenopausal female with osteopenia	BMD OC	Group (Vit K1)—217	5 mg	2 Y	59.2 58.9
				Group (Placebo)—223
				Total—440
[27]	Japan	Postmenopausal female	BMD	Group (Control)—66	45 mg	2 Y	50-75
				Group (Hormone replacement therapy)—66
				Group (Etidronate)—66
				Group (Calcitonin)—66
				Group (Alfacalcidol)—66
				Group (Vit K)—66
				Total- 396
[15]	Korea	Postmenopausal female	BMD	Group (Vit K2)—38	15 mg	6 M	>60
				Group (Control)—40
				Total—78
[28]	Japan	Postmenopausal, female osteoporosis	Serum Uncarboxylated OC, incidence of fracture	Group (Risedronate)—51	45 mg	1 Y	75
				Group (Risedronate + Vit K2)—50
				Total—101
[2]	Japan	Postmenopausal, female	BMD OC Uncarboxylated OC	Group (Vit K2)—33	45 mg	48 W	60–75
				Group (Control)—30
				Total—63
[23]	Washington	Free living male and postmenopausal female	BMD OC Uncarboxylated OC	Group (Vit K)—189	500 µg	3 y	68 ± 6
				Group (No treatment)—190
				Total—379
[9]	Norway	Postmenopausal female	BMD OC	Group K2(MK-7))—167	360 µg	1 Y	60
				Group (Placebo)—167
				Total—334
[21]	Japan	Cirrhosis + viral hepatitis, female	BMD	Group (Vit K2)—25	15 mg	2 Y	59 ± 9 61± 8
				Group (Control)—25
				Total—50
[29]	Japan	Osteoporosis, female	LBMD CF	Group Control (Calcium)—121	45 mg	24 M	-
				Group (Vit K 2)—120
				Total- 241
[30]	Japan	Female, uterine leiomyomas/endometriosis	BMD	Group(Leuprolide acetate)—28	45 mg	6 M	46.2 ± 0.5
				Group (Leuprolide acetate + vit K2)—28
				Group (Leuprolide acetate + Rocaltrol)—26
				Group (Leuprolide acetate + Vit K + Rocaltrol)—28
				Total—110
[17]	America	Pre and perimenopausal female, cirrhosis	BMD	Group (Vit K)	600 µg	6 M	25–50 Y
				Group (Placebo)
				Total—14
[31]	America	Postmenopausal female	BMD	Group (Placebo)—129	1 mg 15 mg	12 M	62.4 (0.6) 62.7 (0.7) 62.4 (0.7)
				Group (Vit K1)—126
				Group (MK- 4)—126
				Total—381
[32]	Netherland	Postmenopausal female	BMD	Group (Placebo)—164	45 mg	3 Y	66.0 ± 0.5 65.9 ± 0.4
				Group (Vit K2)—161
				Total—325
[33]	Netherland	Healthy, Postmenopausal female	BMD BMC	Group (Placebo)—124	180 µg	3 Y	55–65 Y
				Group (MK—7)—120
				Total—240
[34]	Japan	Postmenopausal female	BMD BMC VF	Group (Control)—19	45 mg	1 Y	53.690± 84 55.991± 55 52.691± 76 53.390 ±76
				Group (Vit K2)—17
				Group (Vit D2)—16
				Group (Hormone Replacement Therapy)—23
				Total—72
[35]	UK	Healthy, female	BMD	Group (Placebo)—61	200 µg	2 Y	>60
				Group (Vit K1)—60
				Group (VitD3+ Ca)—62
				Group (VitK1+D3+ Ca)—61
				Total—244
[3]	Nigeria	Osteoporotic female	BMD Serum OC	Group (Vit K 2)—70	15 mg	6 M	64.07 ± 9.63
				Group (Strontium renate)—70
				Group (Control)—70
				Total—210